Nevada Clinical Trials

A listing of Nevada clinical trials actively recruiting patient volunteers.

Nevada may be best known for the Las Vegas Strip, but there's plenty to see outside it. Carson City, Reno, and Virginia City all hold their own charms for visitors and residents alike. A vast state with a low population density, it remains the 4th largest producer of gold in the world, even after many Gold Rush "boom towns" have long since been exhausted. As much of the state is dotted with small communities, the best healthcare is centered on larger cities. The Las Vegas area's Sunrise Hospital & Medical Cente is the biggest provider, with more than 640 beds.

Filter by Condition
659 trials found

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

NCT04697758

This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with Diabetic Macular Edema (DME).

Conditions: Diabetic Macular Edema (DME)
Phase: Phase 1/2

Low Level Laser Therapy (LLLT) for the Treatment of Hand Osteoarthritis.

NCT04692597

This study is a randomized, control trial of Active Duty and DoD Beneficiaries, age 18 years or older, with complaints of hand osteoarthritis. Subjects will be randomized into one of two groups receiving either LLLT or sham LLLT. Subjects will receive LLLT or sham LLLT weekly over a period of six weeks. At each visit, patients will rate their pain using the Defense and Veterans Pain Rating Scale (DVPRS) and assess their functionality using the Disabilities of the Arm, Shoulder, and Hand (DASH) q ...

Conditions: Low Level Laser Therapy, Osteoarthritis, Family Medicine, Pain Management, Integrative Medicine
Phase: Not Applicable

A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

NCT04688931

This is a global, randomized, controlled, open-label Phase 3 study designed to assess the long-term efficacy and safety of UGN-102 (mitomycin) for intravesical solution with or without (±) transurethral resection of bladder tumors (TURBT) versus TURBT alone for the treatment of patients with low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC).

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

NCT04686136

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine

Conditions: Episodic Migraine, Chronic Migraine

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

NCT04684394

This study is designed to investigate the safety and tolerability of GEM103 IVT injection + standard of care vs. sham + standard of care.

Conditions: Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration, Macular Degeneration

Study of HL-085 in Patients With Advanced Solid Tumor Tumors

NCT04683354

The investigational product (IP) HL-085 is an adenosine triphosphate-noncompetitive mitogen activated protein kinase (MEK) inhibitor with a strong selective anti-tumor activity, with a much lower dose than selumetinib. It has been shown strong anti-tumor activities in preclinical studies to treat solid tumors, e.g., melanoma, non-small cell lung cancer, colon cancer and other malignancies with RAF and RAS mutations. Kechow has completed phase I dose escalation study to test HL-085 in patients w ...

Conditions: Solid Tumor, Adult

A Single Oral Dose Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects

NCT04680429

This Phase I first in man study in healthy volunteers is intended to evaluate safety and pharmacokinetics of singe ascending doses of RP7214 a DHODH inhibitor. This is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and PK of RP7214 in HVs.

Conditions: Healthy Volunteers

Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm

NCT04671082

This is a double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of tolperisone (a non-opioid) or placebo administered in subjects with pain due to acute back muscle spasm.

Conditions: Back Muscle Spasm, Back Pain, Back Strain, Back Spasm Upper, Muscle Spasm, Acute Pain

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

NCT04666441

The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo. The secondary objectives of the study are: To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compared to placebo To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo To assess the concentrations of REGN10933 and REGN10987 in serum over time

Conditions: COVID-19

A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

NCT04659161

This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and Statistical Manual Fifth Edition (DSM-5) diagnosis of schizophrenia. The primary objective of the study is to assess the efficacy of KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) versus placebo in reducing Positive and Negative Synd ...

Conditions: Schizophrenia, Schizophrenia; Psychosis

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

NCT04659174

This is a Phase 3, multicenter, 53-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5) schizophrenia who previously completed the treatment period of one of the two Phase 3 double-blind studies, KAR-007 or KAR-009. In this OLE study, all subjects will receive KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily [BID]) for ...

Conditions: Schizophrenia

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

NCT04658186

The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with early-stage Parkinson's Disease.

Conditions: Early-stage Parkinson's Disease